BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
NEW YORK, March 28, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of investors who purchased BioAmber Inc. (“BioAmber”) (NYSE:BIOA) securities (1) pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017; and/or (2) on the open market from January 23, 2017 through March 16, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/bioamber-inc. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, BioAmber made materially false and/or misleading statements and/or failed to disclose that: (1) a large customer of BioAmber that was expected to purchase $2.8 million of succinic acid in Q4 2016 experienced a technical problem in its manufacturing facility and postponed the order to 2017; and (2) as a result, defendants’ statements about BioAmber’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in BioAmber you have until May 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/bioamber-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
